Indivior PLC (2IVB.BE)
| Previous close | 20.50 |
| Open | 20.50 |
| Bid | 20.50 x N/A |
| Ask | 20.75 x N/A |
| Day's range | 20.50 - 20.50 |
| 52-week range | 15.09 - 22.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a retrospective chart review analysis of individuals treated for opioid use disorder (OUD) demonstrating that in Canada SUBLOCADE® (buprenorphine extended-release) Injection was associated with a lower incidence rate (number of events per 100 person-years) of self-reported, non-fatal opioid overdoses (1.7%) compared with sublingual buprenorphine/naloxone (19.3%) or methadone (46.8%) leading to a statistically significant risk adj
- PR Newswire
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL"). The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL. The Agreement is subject to initial approval by the U
- PR Newswire
Indivior Announces Q2/H1 2023 Financial Results
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.
